Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Responses seen in CLL patients given cenersen added to chemo-immunotherapy

Dec. 11, 2009

JAK2 inhibitor SB-1518 shows promise against hematological malignancies

Dec. 11, 2009

Rufinamide efficacious in adults and children with epilepsy

Dec. 10, 2009

Pfizer's p38 MAPK inhibitor PHA-666859 shows potential to treat diabetic retinopathy

Dec. 10, 2009

CPX-351 safety appears acceptable in older patients with acute myeloid leukemia

Dec. 10, 2009

Pazopanib increases visual acuity in phase II macular degeneration study

Dec. 10, 2009

Promising phase I and II data on foretinib in solid tumor therapy

Dec. 10, 2009

Multiple phase I studies of Exelixis oncolytic products reported

Dec. 10, 2009

Preclinical and early phase I data suggest activity of JI-101 in solid tumors

Dec. 9, 2009

AJM-300 shows clinical activity in patients with active Crohn's disease

Dec. 9, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...